AzTrials
AzTrials

Food AllergyNCT02341040

Evaluation of Potential Allergenicity of New Wheat Varieties

An observational study of Food Allergy and Wheat Allergy, run by University of Colorado, Denver at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The goal of the study is to determine accurate blood test levels that can predict whether or not subjects are truly allergic to certain foods. In this study, subjects that are clinically documented to be wheat-allergic will participate in a double blind oral food challenge. Read more about this study

Who is it for?
Ages 1 year to 21 yearsHealthy volunteers can take part
Conditions the study is for
Food Allergy, Wheat Allergy
How many people
5 participants
Where
1 siteUnited States
Study dates
Nov 2014to 15 May 2018
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year to 21 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Study population: Pediatric and adult subjects between the ages of 1 (inclusive) to 21 years (inclusive) that have sensitivity to wheat

Who may be able to join

  • Age 1 year to 21 years of any sex and any race
  • Physician-diagnosed food allergy to wheat with convincing clinical history of food allergy to wheat AND a skin prick test positive to wheat (diameter of wheal 3 mm or greater than negative control) or a detectable serum food-specific IgE level (ImmunoCAP > 0.35 kUA/L) to wheat within the previous 12 months or at the time of entry into the study
  • If no history of clinical reactivity to wheat, then a positive skin prick test to wheat (diameter of wheal 3 mm or greater than negative control) OR a detectable serum food-specific IgE level to wheat within the previous 12 months or at the time of entry into the study
  • Patients who meet any of the following criteria are eligible for enrollment as study participants if they meet all other criteria, but will not undergo a DBPCFC:
  • Recent (within one year) failed open OFC
  • Positive DBPCFC to wheat at CHCO
Show all 10Show fewer
  • Recent (within one year) exposure to wheat resulting in immediate IgE-mediated allergic symptoms (within 2 hours of ingestion; symptoms such as urticaria, angioedema, congestion, rhinorrhea, wheezing, respiratory compromise, hypoxia, hypotension)
  • Written informed consent from parent/guardian and assent (when age appropriate).
  • Willingness to submit specimen for laboratory serum IgE testing
  • Willingness to submit lab specimen for ELISA testing

Who cannot join

  • Inability to discontinue antihistamines for skin prick testing and OFCs
  • FEV1 value <80% predicted OR any clinical features of moderate or severe persistent asthma, as defined by the 2007 NHLBI guidelines table for classifying asthma, at the time of entry into the study
  • Use of >500 μg/day fluticasone or equivalent
  • Asthma requiring either:
  • 1 hospitalization in the past year for asthma, or
  • 1 ER visit in the past 6 months for asthma
Show all 13Show fewer
  • Use of steroid medications (IV, IM or oral) for asthma in the following manners:
  • history of daily oral steroid dosing for >1 month during the past year, or
  • steroid course/burst in the past 3 months (except for steroid dosing used in the treatment of an allergic reaction during the DBPCFC), or
  • 2 steroid courses/bursts in the past year.
  • History of intubation due to allergies or asthma
  • Diagnosis of active eosinophilic gastrointestinal disease in the past year
  • Severe atopic dermatitis, as assessed by a Three-Item Severity Score of 6 or greater

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Children's Hospital Colorado

    Aurora, Colorado, 80045

Other trials in United States

About this study

The goal of the study is to determine accurate blood test levels that can predict whether or not subjects are truly allergic to certain foods. In this study, subjects that are clinically documented to be wheat-allergic will participate in a double blind oral food challenge. Blood will be collected from the subject to evaluate the potential allergenicity of proteins introduced into genetically modified crops and evaluate wheat-specific immunoglobulin-e (IgE) antibody reactivity to biotech and conventional wheat varieties.

Read the detailed description

The prevalence of food allergy is increasing in the pediatric population. A diagnosis of food allergy carries significant medical, nutritional, and psychological implications for both patients and their families. Therefore, making an accurate diagnosis is critical. However, the diagnosis of symptomatic food allergy continues to be a challenge for allergists and other practicing physicians. The patient's clinical history remains a key component in diagnosing food allergy. Skin prick testing and food-specific immunoglobulin-e (IgE) testing act as secondary tools to aid in the evaluation process, but these tests also suffer from a high rate of false positivity. For specific IgE levels below the cutoffs to these foods, however, supervised oral food challenges (OFCs) may be necessary to establish the diagnosis of symptomatic food allergy, as the sensitivity of these values is relatively low. Currently, the double-blind, placebo-controlled food challenge (DBPCFC) remains the gold standard for the diagnosis of food allergy. OFCs have their own inherent drawbacks: they are not always readily available to all patients, they are time-consuming, and they are potentially dangerous due to their risk of anaphylaxis.

Wheat is one of the eight allergenic foods that are responsible for approximately 90% of all food allergies. Wheat is less allergenic than other foods in this group and less likely to cause multi-organ, severe, life-threatening reactions. Allergy to wheat is more prevalent in children than adults and is considered a transient allergy of infancy/childhood. Wheat allergy is often outgrown in early childhood, in most cases by age 3-5 years, but 35% show a persistent allergy into adolescence. While previous studies using food-specific IgE antibodies have determined diagnostic decision points that indicate a high likelihood of clinical reactivity for certain foods, namely milk, egg, peanut, and fish, wheat-specific IgE levels do not seem to be useful predictors of food challenge outcome, enabling reduction in need for food challenges. Furthermore, false-positive IgE reactions to wheat and other cereals are frequently seen in grass-allergic patients due to insignificant cross-reactivity between water/salt-soluble proteins. Therefore, identification of wheat proteins associated with symptoms to wheat is of importance.

Gliadins in particular have been implicated in allergy to wheat, both in IgE-mediatedallergy and the non-IgE mediated celiac allergy. IgE antibodies to ω-5-gliadin have been found in children with immediate reactions to ingested wheat, and published results show that increased levels of IgE to ω-5-gliadin correlate with the outcome of food challenges. In a Finnish study, all children with IgE antibodies to ω-5-gliadin reacted with immediate symptoms to wheat challenges, while all patients with delayed or negative challenge test results showed no detectable IgE antibodies to ω-5-gliadin.15 In a Japanese cohort, the presence of elevated ω-5-gliadin-specific IgE antibodies was associated with immediate symptoms with wheat food challenges and also in patients with a strong convincing history of wheat allergy who were not challenged due to risk of anaphylaxis. Furthermore, patients with severe reactions upon challenge had significantly higher levels of ω-5-gliadin-specific IgE antibodies compared to children with mild or moderate symptoms. In a multicenter Japanese study, Ebisawa et al. showed a significant relationship between the probability of wheat allergy and the concentration of ω-5-gliadin-specific IgE antibodies with 2.6-fold increased risk. In a study of mixed German and American subjects, ω-5-gliadin-specific IgE antibodies did not correlate with food challenge outcomes in patients with suspected allergy. However, the sample size in this study was much smaller than in others, and the German population included more patients with non-IgE mediated wheat allergy with delayed symptoms, almost half of the German cohort. Nonetheless, ω-5-gliadin-specific IgE antibodies may differ among populations in Asia, Europe, and the United States due to dietary habits and genetics, and further study is warranted, especially in a larger U.S. cohort.

Food crops that have been developed through agricultural biotechnology for commercial use are thoroughly assessed for their safety. One of the key elements in the safety assessment of a genetically improved crop is an evaluation of potential changes in their allergenic properties. Allergenic properties of the crop can potentially be altered if a known allergen or a protein that has high potential to become an allergen is introduced. In addition, the level of expression of endogenous allergens might be altered as a result of transformation and insertion of the new gene into the plant genome.

Since wheat is a known allergenic food crop, international guidelines require analyses to determine if the introduction of the genes and production of the recombinant proteins in wheat cause an unintended change in the levels of endogenous allergenic proteins. To address this question, levels of wheat-specific IgE binding observed in the biotechnology derived wheat varieties are compared to the set of binding values observed in reference wheat varieties that are already on the market. Determining the levels of direct IgE binding using an enzyme linked immuno-sorbent assay (ELISA) has been shown to be an appropriate method to perform such comparisons, especially when the assay is validated and calibrated prior to the production of data. This comparison is important as it will enable determinations of whether there is heterogeneity in wheat-allergic patients with wheat allergy in terms of a predominant trigger. Ultimately, crops may be engineered to eliminate culprit components if predominant.

Food challenge outcomes and standard ImmunoCAP IgE assays to wheat will be compared to CRD wheat testing in this study (Thermo Fisher Scientific, Waltham, MA). When evaluated together with clinical history, skin test reactivity, and OFC outcomes, responses to individual components may be able be used to predict food challenge responsiveness. With respect to intact wheat-specific IgE levels, in two previous studies using these, a true 95% positive predictive value cutoff to predict reactivity at OFC could not be determined to wheat, although a physician challenge was suggested at an estimated wheat level of 26 kU/L to determine possible reactivity.6,7 However, these studies are now over a decade old and pre-dated component resolved diagnostics (CRD). CRD to major proteins ω-5-gliadin may prove to be more beneficial in determining predictive levels of IgE and positive OFC outcomes to wheat. Therefore, in addition to determining wheat component patterns that could predict OFC outcomes, the investigators hope to determine 95% predictive decision points for each of the individual components and compare these to the decision points estimated by the ImmunoCAP assay to wheat.

Keywords
wheat allergy, food allergy, pediatric
Medical subject headings
Food Hypersensitivity, Wheat Hypersensitivity

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Determine the relationship between whole wheat-specific IgE and IgE to components

    Logistic regression analyses will be performed to establish diagnostic decision pointsindicating a high likelihood of symptomatic food allergy to wheat, thus potentiallypreventing unnecessary food challenges for patients with wheat allergy..

    Measured: ~2 weeks

Secondary outcomes (4)
  1. Determine the relationship between IgE components and oral food challenge

    The investigators will evaluate IgE to components Tri a 14, Tri a 19, and Tri a Aa_TI, and Oral Food Challenges outcomes.

    Measured: ~2 weeks

  2. Determine the Cross-Reactivity between wheat and grass allergens

    To assess cross-reactivity between wheat and grass allergens in wheat-allergic patients.

    Measured: ~1 month

  3. Determine the Potential Allergenicity

    To evaluate the potential allergenicity of putative wheat allergens.

    Measured: ~1 month

  4. Establish a Serum Repository

    To establish a serum repository at Monsanto of wheat-reactive allergic patients.

    Measured: ~2 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Jan 2015 (estimated)
  2. Study startNov 2014
  3. Primary completion15 May 2018
  4. Study completion15 May 2018

Why it stopped: insufficient subjects recruited in allotted time

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
5 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02341040
Sponsor's protocol ID
14-1416
Other IDs
UL1TR001082
Status last verified
May 2018
First submitted
6 Jan 2015
Last updated
21 May 2018
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Food Allergy and Wheat Allergy, run by University of Colorado, Denver at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 21 May 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: insufficient subjects recruited in allotted time). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Determine the relationship between whole wheat-specific IgE and IgE to components (time frame: ~2 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 May 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in